Patients with testicular germ cell tumors are highly curable with either surgery, chemotherapy, and radiation therapy or multimodality therapy. However, a subset of patients with poor prognosis disease still die of refractory and relapsed disease. Recent studies have focused on limiting therapy-related toxicities in patients with good prognosis disease and improving the survival rate in patients with poor prognosis disease.